Search Within

Jahan Aghalar

Formats
  1. Meeting Abstract (6)
  2. Journal Article (2)
Groups
  1. Department of Medicine (8)
  2. Solid Tumor Oncology Division (8)
  3. Genitourinary Oncology Service (5)
  4. Radiation Oncology, Department of (5)
  5. Survivorship Research (5)
  6. Weinberg Fellows (5)

More Groups

People
  1. Sean McBride (5)
  2. Han Xiao (4)
  3. Alan Ho (3)
  4. Chiaojung Jillian Tsai (3)
  5. Daniel McFarland (3)
  6. David Pfister (3)

More People

Years
  1. 2021 (1)
  2. 2020 (1)
  3. 2019 (2)
  4. 2018 (4)
Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer (1)
Publishers
  1. American Society of Clinical Oncology (7)
  2. Wiley Blackwell (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma
    Journal Article

    McBride, S.; Sherman, E.; Tsai, C. J.; Baxi, S.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D.; Michel, L. S.; Young, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
    Journal Article

    Feldman, D. R.; Ged, Y.; Lee, C. H.; Knezevic, A.; Molina, A. M.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Murray, S.; Tickoo, S. K.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    McBride, S. M.; Lee, N. Y.; Pfister, D. G.; Sherman, E. J.; Tsai, C. J.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D. C.; Michel, L. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Paller, C. J.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W. D.; Den, R. B.; Deville, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W.; Den, R. B.; Deville, C.; Borofsky, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    McBride, S. M.; Sherman, E. J.; Tsai, C. J.; Baxi, S. S.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D. C.; Michel, L. S.; Spielsinger, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial
    Meeting Abstract

    Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression
    Meeting Abstract

    Kelly, W. K.; Godwin, J. L.; Hoffman-Censits, J. H.; Knudsen, K. E.; De Leeuw, R.; Leiby, B. E.; Southwell, T.; Hubert, C.; Smith, D. C.; Chatta, G. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save